GCM
IPXL

Graham Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Graham Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-24,200
Closed -$390K – 98
2017
Q2 		$390K Buy
+24,200
New +$357K 0.01% 82

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Graham Capital Management's IPXL Position: Q3 2017 in Review

Graham Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q3 2017, closing a stake of 24,200 shares — an estimated $390K sold.

Graham Capital Management first reported a position in IPXL in Q2 2017 and held it in 1 quarter. The position peaked at $390K in Q2 2017. 189 funds tracked by Wall St. Rank hold IPXL as of Q3 2017.

  • Graham Capital Management reported no remaining Impax Laboratories, Inc. position as of Q3 2017 after selling out during the quarter.
  • Graham Capital Management sold 24,200 Impax Laboratories, Inc. shares in Q3 2017, an estimated $390K.
  • Graham Capital Management first reported a position in Impax Laboratories, Inc. in Q2 2017 and held it in 1 quarter.
  • Graham Capital Management's Impax Laboratories, Inc. position peaked at $390K in Q2 2017.
  • 189 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2017.

Based on Graham Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.